TY - JOUR T1 - Hemodynamic and clinical performance of Solo stentless bioprosthetic aortic valves JO - Revista Portuguesa de Cardiologia (English edition) T2 - AU - Andrade,Marta AU - Saraiva,Francisca AU - Amorim,Mário J. AU - Marinho,Benjamim AU - Cerqueira,Rui J. AU - Lourenço,André P. AU - Pinho,Paulo AU - Almeida,Jorge AU - Leite-Moreira,Adelino F. SN - 21742049 M3 - 10.1016/j.repce.2017.11.020 DO - 10.1016/j.repce.2017.11.020 UR - https://www.revportcardiol.org/en-hemodynamic-clinical-performance-solo-stentless-articulo-S2174204918303519 AB - ObjectiveTo report the hemodynamic profile and short- and medium-term outcomes of Freedom Solo and Solo Smart stentless aortic valves implanted at our center. MethodsBetween 2009 and 2015, all patients undergoing aortic valve replacement using Solo stentless valves at our center were enrolled. Clinical and echocardiographic follow-up was carried out six months postoperatively. Survival and major events, including structural valve deterioration and non-structural valve dysfunction, endocarditis, reoperation and stroke, were assessed through medical records or telephone interview with the referring cardiologist up to November 2015 (mean and maximum follow-up 39±22 and 78 months, respectively). ResultsPatients’ (n=345) mean age was 72±8 years, 52% were female and median euroSCORE II was 2.7 (1.5-4.7). There was no intraoperative mortality and in-hospital mortality was 2.6%. Postoperatively, mean transvalvular gradient was 11.9±4.5 mmHg and effective orifice area was 1.9±0.5 cm2. Patient-prosthesis mismatch occurred in 14% but was severe in only one patient. Cumulative survival at six years was 72%. Six patients were reoperated: three due to endocarditis, two for structural prosthesis deterioration and one because of periprosthetic fistula. Five patients suffered stroke, three had medically-treated endocarditis and one had structural valve deterioration but was not considered suitable for reoperation. None of the remainder had structural valve deterioration or non-structural valve dysfunction. ConclusionsSolo stentless aortic valves are safe to implant, with promising clinical outcomes in short- and medium-term assessment. Moreover, they show an excellent hemodynamic performance: low transvalvular gradients, large effective orifice areas and low incidence of patient-prosthesis mismatch. ER -